ENCRT-Islets for Hypoglycemia

About Encellin

Encellin is a private, clinical-stage biotech based in San Francisco, pioneering a novel cell encapsulation platform. The company's lead application is for hypoglycemia in Type 1 Diabetes, with an interim clinical readout showing promising early results, including non-fibrotic engraftment. Founded on technology from UCSF, Encellin aims to enable durable, off-the-shelf cell replacement therapies across a range of chronic conditions, beginning with high-unmet-need endocrine disorders.

Therapeutic Areas